Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Viva Gold Reports Strong Initial Assay Results for its Fall 2024 Drill Program (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Technology Scientific & Technical Instruments
Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

VentriPoint Diagnostics Ltd > New Press Release - VENTRIPOINT and ASCEND Cardiovascular sign Term Sheet for integration of VMS+ into ASCEND's Gen3Echo(TM) platform
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(16)
•••
Comment by jopatcloon Dec 18, 2024 9:48am
32 Views
Post# 36367839

RE:RE:New Press Release - VENTRIPOINT and ASCEND Cardiovascular sign Term Sheet for integration of VMS+ into ASCEND's Gen3Echo(TM) platform

RE:RE:New Press Release - VENTRIPOINT and ASCEND Cardiovascular sign Term Sheet for integration of VMS+ into ASCEND's Gen3Echo(TM) platformnow 0.105 $ Good comment 
@JSSRYes @LastDance means they can still try and work with GE or other companies.
2
 
 
 
@cardinalAscend is going to sell lots of VMS. Super exciting deal for VPT.
1
 
 
 
@cardinalShould see very steady stream of news now. Exciting stuff for Ventripoint. As well, early word on 4.0 Europe is it will be a huge success
0
 
 
 
@yudi GranhamB's Fud Sheep or Puppets with your fake accounts go to denigrate as usual good news...you be the judge between GranhamB. and Dr. Jeff Soble, CEO of ASCEND Cardiovascular. "ASCEND is on a mission to provide a powerful, fully integrated, best-of-breed echocardiography workflow solution to its customers,” stated Dr. Jeff Soble, CEO of ASCEND Cardiovascular.
0
 
 
 
@cardinalintegrated software with a per sale to Ventripoint. not sure exactly but likely 10k with recurring, They have 50,000 daily users and really love VMS as new sales driver
0
 
 
 
@cardinalGet ready for more large distribution around the world. Remember, They have some of the biggest centres on the planet now and sales will ramp. Their valve solution could be worth billions. This will be sold to a big

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities